Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Brian Murphy

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Physiology

Concepts & Ideas

Temperature

Disorders

Genes & Molecular Sequences

Viral Genes

Anatomy

Cell Line

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
114
Collins, Peter
45
Whitehead, Stephen
41
Skiadopoulos, Mario
41
Chanock, Robert
26
Karron, Ruth
26
Surman, Sonja
24
Firestone, Cai-Yen
23
Durbin, Anna
23
Bukreyev, Alexander
23
Crowe, James
21
Blaney, Joseph
17
Elkins, William
16
Buchholz, Ursula
16
McAuliffe, Josephine
13
Moss, Bernard

Sign-in to see all Coauthors

Publications

TOP 3
Maximova Olga A; Faucette Lawrence J; Ward Jerrold M; Murphy Brian R; Pletnev Alexander G
Cellular inflammatory response to flaviviruses in the central nervous system of a primate host.
Luongo Cindy; Yang Lijuan; Winter Christine C; Spann Kirsten M; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.
Karron Ruth A; Talaat Kawsar; Luke Catherine; Callahan Karen; Thumar Bhagvanji; Dilorenzo Susan; McAuliffe Josephine; Schappell Elizabeth; Suguitan Amorsolo; Mills Kimberly; Chen Grace; Lamirande Elaine; Coelingh Kathleen; Jin Hong; Murphy Brian R; Kemble George; Subbarao Kanta
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Brian Murphy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Maximova Olga A; Faucette Lawrence J; Ward Jerrold M; Murphy Brian R; Pletnev Alexander G
Cellular inflammatory response to flaviviruses in the central nervous system of a primate host.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2009;57(10):973-89.
2009: Luongo Cindy; Yang Lijuan; Winter Christine C; Spann Kirsten M; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.
Vaccine 2009;27(41):5667-76.
2009: Karron Ruth A; Talaat Kawsar; Luke Catherine; Callahan Karen; Thumar Bhagvanji; Dilorenzo Susan; McAuliffe Josephine; Schappell Elizabeth; Suguitan Amorsolo; Mills Kimberly; Chen Grace; Lamirande Elaine; Coelingh Kathleen; Jin Hong; Murphy Brian R; Kemble George; Subbarao Kanta
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.
Vaccine 2009;27(36):4953-60.
2009: Talaat Kawsar R; Karron Ruth A; Callahan Karen A; Luke Catherine J; DiLorenzo Susan C; Chen Grace L; Lamirande Elaine W; Jin Hong; Coelingh Kathy L; Murphy Brian R; Kemble George; Subbarao Kanta
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
Vaccine 2009;27(28):3744-53.
2009: Karron Ruth A; Callahan Karen; Luke Catherine; Thumar Bhagvanji; McAuliffe Josephine; Schappell Elizabeth; Joseph Tomy; Coelingh Kathleen; Jin Hong; Kemble George; Murphy Brian R; Subbarao Kanta
A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.
The Journal of infectious diseases 2009;199(5):711-6.
2009: Dinapoli Joshua M; Ward Jerrold M; Cheng Lily; Yang Lijuan; Elankumaran Subbiah; Murphy Brian R; Samal Siba K; Collins Peter L; Bukreyev Alexander
Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.
Vaccine 2009;27(10):1530-9.
2009: Boonyaratanakornkit Jim B; Bartlett Emmalene J; Amaro-Carambot Emerito; Collins Peter L; Murphy Brian R; Schmidt Alexander C
The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection.
Journal of virology 2009;83(4):1892-910.
2009: Bukreyev Alexander; Marzi Andrea; Feldmann Friederike; Zhang Liqun; Yang Lijuan; Ward Jerrold M; Dorward David W; Pickles Raymond J; Murphy Brian R; Feldmann Heinz; Collins Peter L
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.
Virology 2009;383(2):348-61.
2008: Bukreyev Alexander; Yang Lijuan; Fricke Jens; Cheng Lily; Ward Jerrold M; Murphy Brian R; Collins Peter L
The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.
Journal of virology 2008;82(24):12191-204.
2008: McArthur Julie H; Durbin Anna P; Marron Jennifer A; Wanionek Kimberli A; Thumar Bhavin; Pierro Dennis J; Schmidt Alexander C; Blaney Joseph E; Murphy Brian R; Whitehead Stephen S
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
The American journal of tropical medicine and hygiene 2008;79(5):678-84.
2008: Collins Peter L; Bukreyev Alexander; Murphy Brian R
What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?
Journal of virology 2008;82(19):9805-6.
2008: Bartlett Emmalene J; Cruz Ann-Marie; Esker Janice; Castaño Adam; Schomacker Henrick; Surman Sonja R; Hennessey Margaret; Boonyaratanakornkit Jim; Pickles Raymond J; Collins Peter L; Murphy Brian R; Schmidt Alexander C
Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.
Journal of virology 2008;82(18):8965-77.
2008: Blaney Joseph E; Speicher James; Hanson Christopher T; Sathe Neeraj S; Whitehead Stephen S; Murphy Brian R; Pletnev Alexander G
Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.
Vaccine 2008;26(33):4150-9.
2008: Yang Lijuan; Sanchez Anthony; Ward Jerrold M; Murphy Brian R; Collins Peter L; Bukreyev Alexander
A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
Virology 2008;377(2):255-64.
2008: Bartlett Emmalene J; Hennessey Margaret; Skiadopoulos Mario H; Schmidt Alexander C; Collins Peter L; Murphy Brian R; Pickles Raymond J
Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.
Journal of virology 2008;82(16):8059-70.
2008: Maximova Olga A; Ward Jerrold M; Asher David M; St Claire Marisa; Finneyfrock Brad W; Speicher James M; Murphy Brian R; Pletnev Alexander G
Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates.
Journal of virology 2008;82(11):5255-68.
2008: Wright Peter F; Ankrah Sharon; Henderson Susan E; Durbin Anna P; Speicher Jim; Whitehead Stephen S; Murphy Brian R; Pletnev Alexander G
Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.
Vaccine 2008;26(7):882-90.
2008: Blaney Joseph E; Sathe Neeraj S; Goddard Laura; Hanson Christopher T; Romero Tammy A; Hanley Kathryn A; Murphy Brian R; Whitehead Stephen S
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
Vaccine 2008;26(6):817-28.
2008: DiNapoli Joshua M; Murphy Brian R; Collins Peter L; Bukreyev Alexander
Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection.
Virology journal 2008;5():105.
2008: Bennett Richard S; Cress Christina M; Ward Jerrold M; Firestone Cai-Yen; Murphy Brian R; Whitehead Stephen S
La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys.
Virology journal 2008;5():25.
2007: Jin H; Manetz S; Leininger J; Luke C; Subbarao K; Murphy B; Kemble G; Coelingh K L
Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets.
Vaccine 2007;25(52):8664-72.
2007: DiNapoli Joshua M; Yang Lijuan; Suguitan Amorsolo; Elankumaran Subbiah; Dorward David W; Murphy Brian R; Samal Siba K; Collins Peter L; Bukreyev Alexander
Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.
Journal of virology 2007;81(21):11560-8.
2007: Wright Peter F; Karron Ruth A; Belshe Robert B; Shi Jian R; Randolph Valerie B; Collins Peter L; O'Shea Alice F; Gruber William C; Murphy Brian R
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
Vaccine 2007;25(42):7372-8.
2007: Nolan Sheila M; Skiadopoulos Mario H; Bradley Konrad; Kim Olivia S; Bier Stacia; Amaro-Carambot Emerito; Surman Sonja R; Davis Stephanie; St Claire Marisa; Elkins Randy; Collins Peter L; Murphy Brian R; Schaap-Nutt Anne
Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
Vaccine 2007;25(34):6409-22.
2007: Whitehead Stephen S; Blaney Joseph E; Durbin Anna P; Murphy Brian R
Prospects for a dengue virus vaccine.
Nature reviews. Microbiology 2007;5(7):518-28.
2007: DiNapoli Joshua M; Kotelkin Alexander; Yang Lijuan; Elankumaran Subbiah; Murphy Brian R; Samal Siba K; Collins Peter L; Bukreyev Alexander
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(23):9788-93.
2007: Bukreyev Alexander; Rollin Pierre E; Tate Mallory K; Yang Lijuan; Zaki Sherif R; Shieh Wun-Ju; Murphy Brian R; Collins Peter L; Sanchez Anthony
Successful topical respiratory tract immunization of primates against Ebola virus.
Journal of virology 2007;81(12):6379-88.
2007: Biacchesi Stéphane; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro.
Journal of virology 2007;81(11):6057-67.
2007: Surman Sonja R; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.
Journal of virological methods 2007;141(1):30-3.
2007: Bartlett Emmalene J; Castaño Adam; Surman Sonja R; Collins Peter L; Skiadopoulos Mario H; Murphy Brian R
Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
Virology journal 2007;4():67.
2007: Bennett Richard S; Ton David R; Hanson Christopher T; Murphy Brian R; Whitehead Stephen S
Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes.
Virology journal 2007;4():41.
2007: Blaney Joseph E; Sathe Neeraj S; Hanson Christopher T; Firestone Cai Yen; Murphy Brian R; Whitehead Stephen S
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Virology journal 2007;4():23.
2006: Durbin Anna P; McArthur Julie H; Marron Jennifer A; Blaney Joseph E; Thumar Bhavin; Wanionek Kimberli; Murphy Brian R; Whitehead Stephen S
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
Human vaccines 2006;2(6):255-60.
2006: Bukreyev Alexander; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L
Nonsegmented negative-strand viruses as vaccine vectors.
Journal of virology 2006;80(21):10293-306.
2006: Buchholz Ursula J; Nagashima Kunio; Murphy Brian R; Collins Peter L
Live vaccines for human metapneumovirus designed by reverse genetics.
Expert review of vaccines 2006;5(5):695-706.
2006: Suguitan Amorsolo L; McAuliffe Josephine; Mills Kimberly L; Jin Hong; Duke Greg; Lu Bin; Luke Catherine J; Murphy Brian; Swayne David E; Kemble George; Subbarao Kanta
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
PLoS medicine 2006;3(9):e360.
2006: Pletnev Alexander G; Swayne David E; Speicher Jim; Rumyantsev Alexander A; Murphy Brian R
Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.
Vaccine 2006;24(40-41):6392-404.
2006: Van Cleve William; Amaro-Carambot Emerito; Surman Sonja R; Bekisz Joseph; Collins Peter L; Zoon Kathryn C; Murphy Brian R; Skiadopoulos Mario H; Bartlett Emmalene J
Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.
Virology 2006;352(1):61-73.
2006: Durbin Anna P; McArthur Julie; Marron Jennifer A; Blaney Joseph E; Thumar Bhavin; Wanionek Kim; Murphy Brian R; Whitehead Stephen S
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
Human vaccines 2006;2(4):167-73.
2006: Biacchesi Stéphane; Pham Quynh N; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates.
Journal of virology 2006;80(12):5798-806.
2006: Bukreyev Alexander; Yang Lijuan; Zaki Sherif R; Shieh Wun-Ju; Rollin Pierre E; Murphy Brian R; Collins Peter L; Sanchez Anthony
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
Journal of virology 2006;80(5):2267-79.
2006: Madhi Shabir A; Cutland Clare; Zhu Yuwei; Hackell Jill G; Newman Frances; Blackburn Nigel; Murphy Brian R; Belshe Robert B; Karron Ruth A; Deatly Anne M; Gruber William C; Bernstein David I; Wright Peter F
Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
Vaccine 2006;24(13):2432-9.
2006: Bartlett Emmalene J; Amaro-Carambot Emerito; Surman Sonja R; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.
Vaccine 2006;24(14):2674-84.
2006: Wright Peter F; Karron Ruth A; Madhi Shabir A; Treanor John J; King James C; O'Shea Alice; Ikizler Mine R; Zhu Yuwei; Collins Peter L; Cutland Clare; Randolph Valerie B; Deatly Anne M; Hackell Jill G; Gruber William C; Murphy Brian R
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.
The Journal of infectious diseases 2006;193(4):573-81.
2006: Rumyantsev Alexander A; Murphy Brian R; Pletnev Alexander G
A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice.
Journal of virology 2006;80(3):1427-39.
2006: Skiadopoulos Mario H; Biacchesi Stéphane; Buchholz Ursula J; Amaro-Carambot Emérito; Surman Sonja R; Collins Peter L; Murphy Brian R
Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity.
Virology 2006;345(2):492-501.
2006: Subbarao Kanta; Murphy Brian R; Fauci Anthony S
Development of effective vaccines against pandemic influenza.
Immunity 2006;24(1):5-9.
2006: Rumyantsev Alexander A; Chanock Robert M; Murphy Brian R; Pletnev Alexander G
Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.
Vaccine 2006;24(2):133-43.
2006: Blaney Joseph E; Durbin Anna P; Murphy Brian R; Whitehead Stephen S
Development of a live attenuated dengue virus vaccine using reverse genetics.
Viral immunology 2006;19(1):10-32.
2005: Pham Quynh N; Biacchesi Stéphane; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo.
Journal of virology 2005;79(24):15114-22.
2005: Bukreyev Alexander; Huang Zhuhui; Yang Lijuan; Elankumaran Subbiah; St Claire Marisa; Murphy Brian R; Samal Siba K; Collins Peter L
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Journal of virology 2005;79(21):13275-84.
2005: Biacchesi Stéphane; Pham Quynh N; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates.
Journal of virology 2005;79(19):12608-13.
2005: Kapikian Albert Z; Simonsen Lone; Vesikari Timo; Hoshino Yasutaka; Morens David M; Chanock Robert M; La Montagne John R; Murphy Brian R
A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception.
The Journal of infectious diseases 2005;192 Suppl 1():S22-9.
2005: Nolan Sheila M; Surman Sonja R; Amaro-Carambot Emerito; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.
Vaccine 2005;23(39):4765-74.
2005: Biacchesi Stéphane; Skiadopoulos Mario H; Yang Lijuan; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression.
Journal of virological methods 2005;128(1-2):192-7.
2005: Bartlett Emmalene J; Amaro-Carambot Emerito; Surman Sonja R; Newman Jason T; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
Vaccine 2005;23(38):4631-46.
2005: Stadler Konrad; Roberts Anjeanette; Becker Stephan; Vogel Leatrice; Eickmann Markus; Kolesnikova Larissa; Klenk Hans-Dieter; Murphy Brian; Rappuoli Rino; Abrignani Sergio; Subbarao Kanta
SARS vaccine protective in mice.
Emerging infectious diseases 2005;11(8):1312-4.
2005: Buchholz Ursula J; Biacchesi Stéphane; Pham Quynh N; Tran Kim C; Yang Lijuan; Luongo Cindy L; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L
Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity.
Journal of virology 2005;79(11):6588-97.
2005: Blaney Joseph E; Matro Jennifer M; Murphy Brian R; Whitehead Stephen S
Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Journal of virology 2005;79(9):5516-28.
2005: Karron Ruth A; Wright Peter F; Belshe Robert B; Thumar Bhagvanji; Casey Roberta; Newman Frances; Polack Fernando P; Randolph Valerie B; Deatly Anne; Hackell Jill; Gruber William; Murphy Brian R; Collins Peter L
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
The Journal of infectious diseases 2005;191(7):1093-104.
2005: Durbin Anna P; Whitehead Stephen S; McArthur Julie; Perreault John R; Blaney Joseph E; Thumar Bhavin; Murphy Brian R; Karron Ruth A
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
The Journal of infectious diseases 2005;191(5):710-8.
2005: Roberts Anjeanette; Vogel Leatrice; Guarner Jeannette; Hayes Norman; Murphy Brian; Zaki Sherif; Subbarao Kanta
Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters.
Journal of virology 2005;79(1):503-11.
2005: Collins Peter L; Murphy Brian R
New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.
Proceedings of the American Thoracic Society 2005;2(2):166-73.
2005: Hanley Kathryn A; Goddard Laura B; Gilmore Lara E; Scott Thomas W; Speicher James; Murphy Brian R; Pletnev Alexander G
Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.
Vector borne and zoonotic diseases (Larchmont, N.Y.) 2005;5(1):1-10.
2004: Blaney Joseph E; Hanson Christopher T; Firestone Cai-Yen; Hanley Kathryn A; Murphy Brian R; Whitehead Stephen S
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
The American journal of tropical medicine and hygiene 2004;71(6):811-21.
2004: Belshe Robert B; Newman Frances K; Anderson Edwin L; Wright Peter F; Karron Ruth A; Tollefson Sharon; Henderson Frederick W; Meissner H Cody; Madhi Shabir; Roberton Don; Marshall Helen; Loh Richard; Sly Peter; Murphy Brian; Tatem Joanne M; Randolph Valerie; Hackell Jill; Gruber William; Tsai Theodore F
Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
The Journal of infectious diseases 2004;190(12):2096-103.
2004: Biacchesi Stéphane; Skiadopoulos Mario H; Yang Lijuan; Lamirande Elaine W; Tran Kim C; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate.
Journal of virology 2004;78(23):12877-87.
2004: McAuliffe Josephine; Vogel Leatrice; Roberts Anjeanette; Fahle Gary; Fischer Steven; Shieh Wun-Ju; Butler Emily; Zaki Sherif; St Claire Marisa; Murphy Brian; Subbarao Kanta
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys.
Virology 2004;330(1):8-15.
2004: Blaney Joseph E; Hanson Christopher T; Hanley Kathryn A; Murphy Brian R; Whitehead Stephen S
Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
BMC infectious diseases 2004;4():39.
2004: Hanley Kathryn A; Manlucu Luella R; Manipon Gracielle G; Hanson Christopher T; Whitehead Stephen S; Murphy Brian R; Blaney Joseph E
Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Vaccine 2004;22(25-26):3440-8.
2004: Murphy Brian R; Blaney Joseph E; Whitehead Stephen S
Arguments for live flavivirus vaccines.
Lancet 2004;364(9433):499-500.
2004: Traggiai Elisabetta; Becker Stephan; Subbarao Kanta; Kolesnikova Larissa; Uematsu Yasushi; Gismondo Maria Rita; Murphy Brian R; Rappuoli Rino; Lanzavecchia Antonio
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.
Nature medicine 2004;10(8):871-5.
2004: Skiadopoulos Mario H; Biacchesi Stéphane; Buchholz Ursula J; Riggs Jeffrey M; Surman Sonja R; Amaro-Carambot Emerito; McAuliffe Josephine M; Elkins William R; St Claire Marisa; Collins Peter L; Murphy Brian R
The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.
Journal of virology 2004;78(13):6927-37.
2004: Bukreyev Alexander; Lamirande Elaine W; Buchholz Ursula J; Vogel Leatrice N; Elkins William R; St Claire Marisa; Murphy Brian R; Subbarao Kanta; Collins Peter L
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
Lancet 2004;363(9427):2122-7.
2004: Ison Michael G; Johnston Sebastian L; Openshaw Peter; Murphy Brian; Hayden Frederick
Current research on respiratory viral infections: Fifth International Symposium.
Antiviral research 2004;62(3):75-110.
2004: Buchholz Ursula J; Bukreyev Alexander; Yang Lijuan; Lamirande Elaine W; Murphy Brian R; Subbarao Kanta; Collins Peter L
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(26):9804-9.
2004: Bisht Himani; Roberts Anjeanette; Vogel Leatrice; Bukreyev Alexander; Collins Peter L; Murphy Brian R; Subbarao Kanta; Moss Bernard
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(17):6641-6.
2004: Biacchesi Stéphane; Skiadopoulos Mario H; Tran Kim C; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes.
Virology 2004;321(2):247-59.
2004: Yang Zhi-Yong; Kong Wing-Pui; Huang Yue; Roberts Anjeanette; Murphy Brian R; Subbarao Kanta; Nabel Gary J
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.
Nature 2004;428(6982):561-4.
2004: Subbarao Kanta; McAuliffe Josephine; Vogel Leatrice; Fahle Gary; Fischer Steven; Tatti Kathleen; Packard Michelle; Shieh Wun-Ju; Zaki Sherif; Murphy Brian
Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice.
Journal of virology 2004;78(7):3572-7.
2004: McAuliffe Josephine M; Surman Sonja R; Newman Jason T; Riggs Jeffrey M; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
Journal of virology 2004;78(4):2029-36.
2004: Newman Jason T; Riggs Jeffrey M; Surman Sonja R; McAuliffe Josephine M; Mulaikal Teresa A; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
Journal of virology 2004;78(4):2017-28.
2004: Belshe Robert B; Newman Frances K; Tsai Theodore F; Karron Ruth A; Reisinger Keith; Roberton Don; Marshall Helen; Schwartz Richard; King James; Henderson Frederick W; Rodriguez William; Severs Joseph M; Wright Peter F; Keyserling Harry; Weinberg Geoffrey A; Bromberg Kenneth; Loh Richard; Sly Peter; McIntyre Peter; Ziegler John B; Hackell Jill; Deatly Anne; Georgiu Alice; Paschalis Maribel; Wu Shin-Lu; Tatem Joanne M; Murphy Brian; Anderson Edwin
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
The Journal of infectious diseases 2004;189(3):462-70.
2003: Biacchesi Stéphane; Skiadopoulos Mario H; Boivin Guy; Hanson Christopher T; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Genetic diversity between human metapneumovirus subgroups.
Virology 2003;315(1):1-9.
2003: Chen H; Matsuoka Y; Swayne David; Chen Q; Cox N J; Murphy B R; Subbarao K
Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate.
Vaccine 2003;21(27-30):4430-6.
2003: Blaney Joseph E; Manipon Gracielle G; Firestone Cai Yen; Johnson Daniel H; Hanson Christopher T; Murphy Brian R; Whitehead Stephen S
Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells.
Vaccine 2003;21(27-30):4317-27.
2003: Whitehead Stephen S; Hanley Kathryn A; Blaney Joseph E; Gilmore Lara E; Elkins William R; Murphy Brian R
Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
Vaccine 2003;21(27-30):4307-16.
2003: Pletnev Alexander G; Claire Marisa St; Elkins Randy; Speicher Jim; Murphy Brian R; Chanock Robert M
Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.
Virology 2003;314(1):190-5.
2003: Hanley Kathryn A; Manlucu Luella R; Gilmore Lara E; Blaney Joseph E; Hanson Christopher T; Murphy Brian R; Whitehead Stephen S
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.
Virology 2003;312(1):222-32.
2003: Karron Ruth A; Belshe Robert B; Wright Peter F; Thumar Bhagvanji; Burns Barbars; Newman Frances; Cannon Joan C; Thompson Juliette; Tsai Theodore; Paschalis Maribel; Wu Shin-Lu; Mitcho Yvonne; Hackell Jill; Murphy Brian R; Tatem Joanna M
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
The Pediatric infectious disease journal 2003;22(5):394-405.
2003: Blaney J E; Manipon G G; Murphy B R; Whitehead S S
Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice.
Archives of virology 2003;148(5):999-1006.
2003: Murphy Brian R; Morens David M; Simonsen Lone; Chanock Robert M; La Montagne John R; Kapikian Albert Z
Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions.
The Journal of infectious diseases 2003;187(8):1301-8.
2003: Whitehead Stephen S; Falgout Barry; Hanley Kathryn A; Blaney Jr Joseph E; Markoff Lewis; Murphy Brian R
A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.
Journal of virology 2003;77(2):1653-7.
2003: Skiadopoulos Mario H; Schmidt Alexander C; Riggs Jeffrey M; Surman Sonja R; Elkins William R; St Claire Marisa; Collins Peter L; Murphy Brian R
Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.
Journal of virology 2003;77(2):1141-8.
2003: Skiadopoulos Mario H; Vogel Leatrice; Riggs Jeffrey M; Surman Sonja R; Collins Peter L; Murphy Brian R
The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.
Journal of virology 2003;77(1):270-9.
2003: Chen H; Matsuoka Y; Chen Q; Cox N J; Murphy B R; Subbarao K
Generation and characterization of an H9N2 cold-adapted reassortant as a vaccine candidate.
Avian diseases 2003;47(3 Suppl):1127-30.
2002: Bukreyev Alexander; Skiadopoulos Mario H; McAuliffe Josephine; Murphy Brian R; Collins Peter L; Schmidt Alexander C
More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?
Proceedings of the National Academy of Sciences of the United States of America 2002;99(26):16987-91.
2002: Krempl Christine; Murphy Brian R; Collins Peter L
Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions.
Journal of virology 2002;76(23):11931-42.
2002: Cortez K; Murphy B R; Almeida K N; Beeler J; Levandowski R A; Gill V J; Childs R W; Barrett A J; Smolskis M; Bennett J E
Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation.
The Journal of infectious diseases 2002;186(6):834-8.
2002: Blaney Joseph E; Johnson Daniel H; Manipon Gracielle G; Firestone Cai-Yen; Hanson Christopher T; Murphy Brian R; Whitehead Stephen S
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.
Virology 2002;300(1):125-39.
2002: Murphy Brian R; Collins Peter L
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.
The Journal of clinical investigation 2002;110(1):21-7.
2002: Skiadopoulos Mario H; Surman Sonja R; Riggs Jeffrey M; Elkins William R; St Claire Marisa; Nishio Machiko; Garcin Dominique; Kolakofsky Daniel; Collins Peter L; Murphy Brian R
Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.
Virology 2002;297(1):153-60.
2002: Skiadopoulos Mario H; Surman Sonja R; Riggs Jeffrey M; Orvell Claes; Collins Peter L; Murphy Brian R
Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Virology 2002;297(1):136-52.
2002: Collins Peter L; Murphy Brian R
Respiratory syncytial virus: reverse genetics and vaccine strategies.
Virology 2002;296(2):204-11.
2002: Skiadopoulos Mario H; Tatem Joanne M; Surman Sonja R; Mitcho Yvonne; Wu Shin Lu; Elkins William R; Murphy Brian R
The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
Vaccine 2002;20(13-14):1846-52.
2002: Schmidt Alexander C; Wenzke Daniel R; McAuliffe Josephine M; St Claire Marisa; Elkins William R; Murphy Brian R; Collins Peter L
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Journal of virology 2002;76(3):1089-99.
2002: Hanley Kathryn A; Lee Jay J; Blaney Joseph E; Murphy Brian R; Whitehead Stephen S
Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes.
Journal of virology 2002;76(2):525-31.
2002: Murphy Brian R; Coelingh Kathleen
Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.
Viral immunology 2002;15(2):295-323.
2002: Newman Jason T; Surman Sonja R; Riggs Jeffrey M; Hansen Chris T; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.
Virus genes 2002;24(1):77-92.
2001: Bukreyev A; Belyakov I M; Berzofsky J A; Murphy B R; Collins P L
Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.
Journal of virology 2001;75(24):12128-40.
2001: Troyer J M; Hanley K A; Whitehead S S; Strickman D; Karron R A; Durbin A P; Murphy B R
A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.
The American journal of tropical medicine and hygiene 2001;65(5):414-9.
2001: Durbin A P; Karron R A; Sun W; Vaughn D W; Reynolds M J; Perreault J R; Thumar B; Men R; Lai C J; Elkins W R; Chanock R M; Murphy B R; Whitehead S S
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
The American journal of tropical medicine and hygiene 2001;65(5):405-13.
2001: Skiadopoulos M H; Surman S R; Riggs J M; Collins P L; Murphy B R
A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
Journal of virology 2001;75(21):10498-504.
2001: Nishi H; Senoo M; Nishi K H; Murphy B; Rikiyama T; Matsumura Y; Habu S; Johnson A C
p53 Homologue p63 represses epidermal growth factor receptor expression.
The Journal of biological chemistry 2001;276(45):41717-24.
2001: Crowe J E; Firestone C Y; Murphy B R
Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(7):3910-8.
2001: Blaney J E; Johnson D H; Firestone C Y; Hanson C T; Murphy B R; Whitehead S S
Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.
Journal of virology 2001;75(20):9731-40.
2001: Schmidt A C; Couch R B; Galasso G J; Hayden F G; Mills J; Murphy B R; Chanock R M
Current research on respiratory viral infections: Third International Symposium.
Antiviral research 2001;50(3):157-96.
2001: Tao T; Skiadopoulos M H; Davoodi F; Surman S R; Collins P L; Murphy B R
Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.
Vaccine 2001;19(27):3620-31.
2001: Schmidt A C; McAuliffe J M; Murphy B R; Collins P L
Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Journal of virology 2001;75(10):4594-603.
2001: Harro C D; Pang Y Y; Roden R B; Hildesheim A; Wang Z; Reynolds M J; Mast T C; Robinson R; Murphy B R; Karron R A; Dillner J; Schiller J T; Lowy D R
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Journal of the National Cancer Institute 2001;93(4):284-92.
2000: Bukreyev A; Murphy B R; Collins P L
Respiratory syncytial virus can tolerate an intergenic sequence of at least 160 nucleotides with little effect on transcription or replication in vitro and in vivo.
Journal of virology 2000;74(23):11017-26.
2000: Wright P F; Karron R A; Belshe R B; Thompson J; Crowe J E; Boyce T G; Halburnt L L; Reed G W; Whitehead S S; Anderson E L; Wittek A E; Casey R; Eichelberger M; Thumar B; Randolph V B; Udem S A; Chanock R M; Murphy B R
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
The Journal of infectious diseases 2000;182(5):1331-42.
2000: Feller J A; Smallwood S; Skiadopoulos M H; Murphy B R; Moyer S A
Comparison of identical temperature-sensitive mutations in the L polymerase proteins of sendai and parainfluenza3 viruses.
Virology 2000;276(1):190-201.
2000: Teng M N; Whitehead S S; Bermingham A; St Claire M; Elkins W R; Murphy B R; Collins P L
Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees.
Journal of virology 2000;74(19):9317-21.
2000: Schmidt A C; McAuliffe J M; Huang A; Surman S R; Bailly J E; Elkins W R; Collins P L; Murphy B R; Skiadopoulos M H
Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Journal of virology 2000;74(19):8922-9.
2000: Bukreyev A; Whitehead S S; Prussin C; Murphy B R; Collins P L
Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines.
Journal of virology 2000;74(15):7151-7.
2000: Durbin A P; Skiadopoulos M H; McAuliffe J M; Riggs J M; Surman S R; Collins P L; Murphy B R
Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
Journal of virology 2000;74(15):6821-31.
2000: Tao T; Skiadopoulos M H; Davoodi F; Riggs J M; Collins P L; Murphy B R
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Journal of virology 2000;74(14):6448-58.
2000: Skiadopoulos M H; Surman S R; Durbin A P; Collins P L; Murphy B R
Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
Virology 2000;272(1):225-34.
2000: Munoz F M; Galasso G J; Gwaltney J M; Hayden F G; Murphy B; Webster R; Wright P; Couch R B
Current research on influenza and other respiratory viruses: II international symposium.
Antiviral research 2000;46(2):91-124.
2000: Durbin A P; Elkins W R; Murphy B R
African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection.
Vaccine 2000;18(22):2462-9.
2000: Bailly J E; McAuliffe J M; Durbin A P; Elkins W R; Collins P L; Murphy B R
A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.
Journal of virology 2000;74(7):3188-95.
2000: Gonzalez I M; Karron R A; Eichelberger M; Walsh E E; Delagarza V W; Bennett R; Chanock R M; Murphy B R; Clements-Mann M L; Falsey A R
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.
Vaccine 2000;18(17):1763-72.
2000: Buchholz U J; Granzow H; Schuldt K; Whitehead S S; Murphy B R; Collins P L
Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.
Journal of virology 2000;74(3):1187-99.
2000: Tao T; Davoodi F; Cho C J; Skiadopoulos M H; Durbin A P; Collins P L; Murphy B R
A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Vaccine 2000;18(14):1359-66.
2000: Bailly J E; McAuliffe J M; Skiadopoulos M H; Collins P L; Murphy B R
Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates.
Virus genes 2000;20(2):173-82.
1999: Whitehead S S; Hill M G; Firestone C Y; St Claire M; Elkins W R; Murphy B R; Collins P L
Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
Journal of virology 1999;73(12):9773-80.
1999: Skiadopoulos M H; Tao T; Surman S R; Collins P L; Murphy B R
Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
Vaccine 1999;18(5-6):503-10.
1999: Wyatt L S; Whitehead S S; Venanzi K A; Murphy B R; Moss B
Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
Vaccine 1999;18(5-6):392-7.
1999: Auwaerter P G; Rota P A; Elkins W R; Adams R J; DeLozier T; Shi Y; Bellini W J; Murphy B R; Griffin D E
Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains.
The Journal of infectious diseases 1999;180(4):950-8.
1999: Durbin A P; McAuliffe J M; Collins P L; Murphy B R
Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates.
Virology 1999;261(2):319-30.
1999: Skiadopoulos M H; Surman S R; St Claire M; Elkins W R; Collins P L; Murphy B R
Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
Virology 1999;260(1):125-35.
1999: Juhasz K; Murphy B R; Collins P L
The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination.
Journal of virology 1999;73(6):5176-80.
1999: Durbin A P; Cho C J; Elkins W R; Wyatt L S; Moss B; Murphy B R
Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
The Journal of infectious diseases 1999;179(6):1345-51.
1999: Whitehead S S; Bukreyev A; Teng M N; Firestone C Y; St Claire M; Elkins W R; Collins P L; Murphy B R
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.
Journal of virology 1999;73(4):3438-42.
1999: Juhasz K; Whitehead S S; Boulanger C A; Firestone C Y; Collins P L; Murphy B R
The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations.
Vaccine 1999;17(11-12):1416-24.
1999: Tao T; Skiadopoulos M H; Durbin A P; Davoodi F; Collins P L; Murphy B R
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Vaccine 1999;17(9-10):1100-8.
1999: Bukreyev A; Whitehead S S; Bukreyeva N; Murphy B R; Collins P L
Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2367-72.
1999: Skiadopoulos M H; Surman S; Tatem J M; Paschalis M; Wu S L; Udem S A; Durbin A P; Collins P L; Murphy B R
Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
Journal of virology 1999;73(2):1374-81.
1999: Whitehead S S; Firestone C Y; Karron R A; Crowe J E; Elkins W R; Collins P L; Murphy B R
Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
Journal of virology 1999;73(2):871-7.
1999: Crowe J E; Randolph V; Murphy B R
The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo.
Virus research 1999;59(1):13-22.
1999: Collins P L; Whitehead S S; Bukreyev A; Fearns R; Teng M N; Juhasz K; Chanock R M; Murphy B R
Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.
Advances in virus research 1999;54():423-51.
1998: Crowe J E; Firestone C Y; Crim R; Beeler J A; Coelingh K L; Barbas C F; Burton D R; Chanock R M; Murphy B R
Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.
Virology 1998;252(2):373-5.
1998: Whitehead S S; Firestone C Y; Collins P L; Murphy B R
A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.
Virology 1998;247(2):232-9.
1998: Reed A L; Yamazaki H; Kaufman J D; Rubinstein Y; Murphy B; Johnson A C
Molecular cloning and characterization of a transcription regulator with homology to GC-binding factor.
The Journal of biological chemistry 1998;273(34):21594-602.
1998: Durbin A P; Wyatt L S; Siew J; Moss B; Murphy B R
The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
Vaccine 1998;16(13):1324-30.
1998: Rubinstein Y R; Proctor K N; Bergel M; Murphy B; Johnson A C
Interferon regulatory factor-1 is a major regulator of epidermal growth factor receptor gene expression.
FEBS letters 1998;431(2):268-72.
1998: Whitehead S S; Juhasz K; Firestone C Y; Collins P L; Murphy B R
Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.
Journal of virology 1998;72(5):4467-71.
1998: Crowe J E; Gilmour P S; Murphy B R; Chanock R M; Duan L; Pomerantz R J; Pilkington G R
Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo.
The Journal of infectious diseases 1998;177(4):1073-6.
1998: Tao T; Durbin A P; Whitehead S S; Davoodi F; Collins P L; Murphy B R
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Journal of virology 1998;72(4):2955-61.
1998: Skiadopoulos M H; Durbin A P; Tatem J M; Wu S L; Paschalis M; Tao T; Collins P L; Murphy B R
Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
Journal of virology 1998;72(3):1762-8.
1997: Karron R A; Wright P F; Crowe J E; Clements-Mann M L; Thompson J; Makhene M; Casey R; Murphy B R
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.
The Journal of infectious diseases 1997;176(6):1428-36.
1997: Karron R A; Buonagurio D A; Georgiu A F; Whitehead S S; Adamus J E; Clements-Mann M L; Harris D O; Randolph V B; Udem S A; Murphy B R; Sidhu M S
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(25):13961-6.
1997: Bukreyev A; Whitehead S S; Murphy B R; Collins P L
Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse.
Journal of virology 1997;71(12):8973-82.
1997: Durbin A P; Hall S L; Siew J W; Whitehead S S; Collins P L; Murphy B R
Recovery of infectious human parainfluenza virus type 3 from cDNA.
Virology 1997;235(2):323-32.
1997: Murphy B R; Park E J; Gottlieb P; Subbarao K
An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters.
Vaccine 1997;15(12-13):1372-8.
1997: Juhasz K; Whitehead S S; Bui P T; Biggs J M; Crowe J E; Boulanger C A; Collins P L; Murphy B R
The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.
Journal of virology 1997;71(8):5814-9.
1997: Durbin A P; Siew J W; Murphy B R; Collins P L
Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six.
Virology 1997;234(1):74-83.
1997: Murphy B R; Collins P L
Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
Bulletin of the World Health Organization 1997;75(4):307-13.
1996: Firestone C Y; Whitehead S S; Collins P L; Murphy B R; Crowe J E
Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.
Virology 1996;225(2):419-22.
1996: Wyatt L S; Shors S T; Murphy B R; Moss B
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.
Vaccine 1996;14(15):1451-8.
1996: Karron R A; Makhene M; Gay K; Wilson M H; Clements M L; Murphy B R
Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.
The Pediatric infectious disease journal 1996;15(8):650-4.
1996: Crowe J E; Bui P T; Firestone C Y; Connors M; Elkins W R; Chanock R M; Murphy B R
Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates.
The Journal of infectious diseases 1996;173(4):829-39.
1996: Jin H; Subbarao K; Bagai S; Leser G P; Murphy B R; Lamb R A
Palmitylation of the influenza virus hemagglutinin (H3) is not essential for virus assembly or infectivity.
Journal of virology 1996;70(3):1406-14.
1996: Clements M L; Makhene M K; Karron R A; Murphy B R; Steinhoff M C; Subbarao K; Wilson M H; Wright P F
Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center.
The Journal of infectious diseases 1996;173(1):44-51.
1996: Crowe J E; Firestone C Y; Whitehead S S; Collins P L; Murphy B R
Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.
Virus genes 1996;13(3):269-73.
1995: Subbarao K; Webster R G; Kawaoka Y; Murphy B R
Are there alternative avian influenza viruses for generation of stable attenuated avian-human influenza A reassortant viruses?
Virus research 1995;39(2-3):105-18.
1995: Collins P L; Hill M G; Camargo E; Grosfeld H; Chanock R M; Murphy B R
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11563-7.
1995: Karron R A; Wright P F; Newman F K; Makhene M; Thompson J; Samorodin R; Wilson M H; Anderson E L; Clements M L; Murphy B R
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.
The Journal of infectious diseases 1995;172(6):1445-50.
1995: Subbarao E K; Park E J; Lawson C M; Chen A Y; Murphy B R
Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine.
Journal of virology 1995;69(10):5969-77.
1995: Sun X L; Murphy B R; Li Q J; Gullapalli S; Mackins J; Jayaram H N; Srivastava A; Antony A C
Transduction of folate receptor cDNA into cervical carcinoma cells using recombinant adeno-associated virions delays cell proliferation in vitro and in vivo.
The Journal of clinical investigation 1995;96(3):1535-47.
1995: Moldoveanu Z; Clements M L; Prince S J; Murphy B R; Mestecky J
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.
Vaccine 1995;13(11):1006-12.
1995: Crowe J E; Bui P T; Siber G R; Elkins W R; Chanock R M; Murphy B R
Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization.
Vaccine 1995;13(9):847-55.
1995: Connors M; Crowe J E; Firestone C Y; Murphy B R; Collins P L
A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes.
Virology 1995;208(2):478-84.
1995: Hsu K H; Crowe J E; Lubeck M D; Davis A R; Hung P P; Chanock R M; Murphy B R
Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus.
Vaccine 1995;13(5):509-15.
1995: Kulkarni A B; Collins P L; Bacik I; Yewdell J W; Bennink J R; Crowe J E; Murphy B R
Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.
Journal of virology 1995;69(2):1261-4.
1995: Karron R A; Steinhoff M C; Subbarao E K; Wilson M H; Macleod K; Clements M L; Fries L F; Murphy B R
Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age.
The Pediatric infectious disease journal 1995;14(1):10-6.
1994: Treanor J; Perkins M; Battaglia R; Murphy B R
Evaluation of the genetic stability of the temperature-sensitive PB2 gene mutation of the influenza A/Ann Arbor/6/60 cold-adapted vaccine virus.
Journal of virology 1994;68(12):7684-8.
1994: Crowe J E; Cheung P Y; Wallace E F; Chanock R M; Larrick J W; Murphy B R; Fry K
Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus.
Clinical and diagnostic laboratory immunology 1994;1(6):701-6.
1994: Connors M; Giese N A; Kulkarni A B; Firestone C Y; Morse H C; Murphy B R
Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.
Journal of virology 1994;68(8):5321-5.
1994: Crowe J E; Bui P T; Davis A R; Chanock R M; Murphy B R
A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.
Vaccine 1994;12(9):783-90.
1994: Crowe J E; Bui P T; London W T; Davis A R; Hung P P; Chanock R M; Murphy B R
Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis.
Vaccine 1994;12(8):691-9.
1994: Lawson C M; Bennink J R; Restifo N P; Yewdell J W; Murphy B R
Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.
Journal of virology 1994;68(6):3505-11.
1994: Murphy B R; Hall S L; Kulkarni A B; Crowe J E; Collins P L; Connors M; Karron R A; Chanock R M
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
Virus research 1994;32(1):13-36.
1994: Crowe J E; Murphy B R; Chanock R M; Williamson R A; Barbas C F; Burton D R
Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(4):1386-90.
1993: Subbarao E K; Kawaoka Y; Murphy B R
Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation.
Journal of virology 1993;67(12):7223-8.
1993: Crowe J E; Collins P L; London W T; Chanock R M; Murphy B R
A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.
Vaccine 1993;11(14):1395-404.
1993: Stokes A; Tierney E L; Sarris C M; Murphy B R; Hall S L
The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3).
Virus research 1993;30(1):43-52.
1993: Kulkarni A B; Morse H C; Bennink J R; Yewdell J W; Murphy B R
Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.
Journal of virology 1993;67(7):4086-92.
1993: Epstein S L; Misplon J A; Lawson C M; Subbarao E K; Connors M; Murphy B R
Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(12):5484-93.
1993: Chanock R M; Crowe J E; Murphy B R; Burton D R
Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases.
Infectious agents and disease 1993;2(3):118-31.
1993: de Sierra T M; Kumar M L; Wasser T E; Murphy B R; Subbarao E K
Respiratory syncytial virus-specific immunoglobulins in preterm infants.
The Journal of pediatrics 1993;122(5 Pt 1):787-91.
1993: Steinhoff M C; Fries L F; Karron R A; Clements M L; Murphy B R
Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children.
Journal of clinical microbiology 1993;31(4):836-8.
1993: Subbarao E K; London W; Murphy B R
A single amino acid in the PB2 gene of influenza A virus is a determinant of host range.
Journal of virology 1993;67(4):1761-4.
1993: Hall S L; Sarris C M; Tierney E L; London W T; Murphy B R
A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.
The Journal of infectious diseases 1993;167(4):958-62.
1993: Kulkarni A B; Connors M; Firestone C Y; Morse H C; Murphy B R
The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.
Journal of virology 1993;67(2):1044-9.
1992: Connors M; Kulkarni A B; Firestone C Y; Holmes K L; Morse H C; Sotnikov A V; Murphy B R
Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.
Journal of virology 1992;66(12):7444-51.
1992: Lawson C M; Subbarao E K; Murphy B R
Nucleotide sequence changes in the polymerase basic protein 2 gene of temperature-sensitive mutants of influenza A virus.
Virology 1992;191(1):506-10.
1992: Barbas C F; Crowe J E; Cababa D; Jones T M; Zebedee S L; Murphy B R; Chanock R M; Burton D R
Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(21):10164-8.
1992: Hsu K H; Lubeck M D; Davis A R; Bhat R A; Selling B H; Bhat B M; Mizutani S; Murphy B R; Collins P L; Chanock R M
Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
The Journal of infectious diseases 1992;166(4):769-75.
1992: Subbarao E K; Perkins M; Treanor J J; Murphy B R
The attenuation phenotype conferred by the M gene of the influenza A/Ann Arbor/6/60 cold-adapted virus (H2N2) on the A/Korea/82 (H3N2) reassortant virus results from a gene constellation effect.
Virus research 1992;25(1-2):37-50.
1992: Stokes A; Tierney E L; Murphy B R; Hall S L
The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain.
Virus research 1992;25(1-2):91-103.
1992: Chanock R M; Parrott R H; Connors M; Collins P L; Murphy B R
Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.
Pediatrics 1992;90(1 Pt 2):137-43.
1992: Subbarao E K; Kawaoka Y; Ryan-Poirier K; Clements M L; Murphy B R
Comparison of different approaches to measuring influenza A virus-specific hemagglutination inhibition antibodies in the presence of serum inhibitors.
Journal of clinical microbiology 1992;30(4):996-9.
1992: Clements M L; Subbarao E K; Fries L F; Karron R A; London W T; Murphy B R
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers.
Journal of clinical microbiology 1992;30(3):655-62.
1992: Hall S L; Stokes A; Tierney E L; London W T; Belshe R B; Newman F C; Murphy B R
Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys.
Virus research 1992;22(3):173-84.
1992: Powers D C; Murphy B R; Fries L F; Adler W H; Clements M L
Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies.
Journal of the American Geriatrics Society 1992;40(2):163-7.
1992: Connors M; Kulkarni A B; Collins P L; Firestone C Y; Holmes K L; Morse H C; Murphy B R
Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
Journal of virology 1992;66(2):1277-81.
1992: Connors M; Collins P L; Firestone C Y; Sotnikov A V; Waitze A; Davis A R; Hung P P; Chanock R M; Murphy B R
Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
Vaccine 1992;10(7):475-84.
1992: Subbarao E K; Murphy B R
A general overview of viral vaccine development.
Advances in experimental medicine and biology 1992;327():51-8.
1991: Hall S L; Murphy B R; van Wyke Coelingh K L
Protection of cotton rats by immunization with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus.
Vaccine 1991;9(9):659-67.
1991: Treanor J J; Buja R; Murphy B R
Intragenic suppression of a deletion mutation of the nonstructural gene of an influenza A virus.
Journal of virology 1991;65(8):4204-10.
1991: Muelenaer P M; Henderson F W; Hemming V G; Walsh E E; Anderson L J; Prince G A; Murphy B R
Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections.
The Journal of infectious diseases 1991;164(1):15-21.
1991: Treanor J J; Tierney E L; London W T; Murphy B R
Characterization of the attenuating M and NP gene segments of the avian influenza A/Mallard/78 virus during in vitro production of avian-human reassortant vaccine viruses and after replication in humans and primates.
Vaccine 1991;9(7):495-501.
1991: Muster T; Subbarao E K; Enami M; Murphy B R; Palese P
An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(12):5177-81.
1991: Clements M L; Belshe R B; King J; Newman F; Westblom T U; Tierney E L; London W T; Murphy B R
Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.
Journal of clinical microbiology 1991;29(6):1175-82.
1991: Steinhoff M C; Halsey N A; Fries L F; Wilson M H; King J; Burns B A; Samorodin R K; Perkis V; Murphy B R; Clements M L
The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children.
The Journal of infectious diseases 1991;163(5):1023-8.
1991: Edwards K M; King J C; Steinhoff M C; Thompson J; Clements M L; Wright P F; Murphy B R
Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children.
The Journal of infectious diseases 1991;163(4):740-5.
1991: Murphy B R; Prince G A; Collins P L; Hildreth S W; Paradiso P R
Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
Vaccine 1991;9(3):185-9.
1991: Powers D C; Fries L F; Murphy B R; Thumar B; Clements M L
In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.
Journal of clinical microbiology 1991;29(3):498-505.
1991: Connors M; Collins P L; Firestone C Y; Murphy B R
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.
Journal of virology 1991;65(3):1634-7.
1991: Kanesaki T; Murphy B R; Collins P L; Ogra P L
Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus.
Journal of virology 1991;65(2):657-63.
1990: Murphy B R; Sotnikov A V; Lawrence L A; Banks S M; Prince G A
Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
Vaccine 1990;8(5):497-502.
1990: Steinhoff M C; Halsey N A; Wilson M H; Burns B A; Samorodin R K; Fries L F; Murphy B R; Clements M L
Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children.
The Journal of infectious diseases 1990;162(2):394-401.
1990: van Wyke Coelingh K L; Winter C C; Tierney E L; Hall S L; London W T; Kim H W; Chanock R M; Murphy B R
Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
Journal of virology 1990;64(8):3833-43.
1990: Murphy B R; Prince G A; Lawrence L A; Croen K D; Collins P L
Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV.
Virus research 1990;16(2):153-62.
1990: Prince G A; Hemming V G; Horswood R L; Baron P A; Murphy B R; Chanock R M
Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats.
Journal of virology 1990;64(6):3091-2.
1990: Clements M L; Snyder M H; Sears S D; Maassab H F; Murphy B R
Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers.
The Journal of infectious diseases 1990;161(5):869-77.
1990: Collins P L; Purcell R H; London W T; Lawrence L A; Chanock R M; Murphy B R
Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.
Vaccine 1990;8(2):164-8.
1990: Treanor J J; Tierney E L; Zebedee S L; Lamb R A; Murphy B R
Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice.
Journal of virology 1990;64(3):1375-7.
1990: Flexner C; Moss B; London W T; Murphy B R
Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.
Vaccine 1990;8(1):17-21.
1990: Snyder M H; London W T; Maassab H F; Chanock R M; Murphy B R
A 36 nucleotide deletion mutation in the coding region of the NS1 gene of an influenza A virus RNA segment 8 specifies a temperature-dependent host range phenotype.
Virus research 1990;15(1):69-83.
1989: Murphy B R; Sotnikov A; Paradiso P R; Hildreth S W; Jenson A B; Baggs R B; Lawrence L; Zubak J J; Chanock R M; Beeler J A
Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
Vaccine 1989;7(6):533-40.
1989: Murphy B R; Buckler-White A J; London W T; Snyder M H
Characterization of the M protein and nucleoprotein genes of an avian influenza A virus which are involved in host range restriction in monkeys.
Vaccine 1989;7(6):557-61.
1989: Powers D C; Sears S D; Murphy B R; Thumar B; Clements M L
Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.
Journal of clinical microbiology 1989;27(12):2666-71.
1989: Snyder M H; London W T; Maassab H F; Murphy B R
Attenuation and phenotypic stability of influenza B/Texas/1/84 cold-adapted reassortant virus: studies in hamsters and chimpanzees.
The Journal of infectious diseases 1989;160(4):604-10.
1989: Wathen M W; Brideau R J; Thomsen D R; Murphy B R
Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector.
The Journal of general virology 1989;70 ( Pt 10)():2625-35.
1989: Murphy B R; Collins P L; Lawrence L; Zubak J; Chanock R M; Prince G A
Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.
The Journal of general virology 1989;70 ( Pt 8)():2185-90.
1989: Treanor J J; Snyder M H; London W T; Murphy B R
The B allele of the NS gene of avian influenza viruses, but not the A allele, attenuates a human influenza A virus for squirrel monkeys.
Virology 1989;171(1):1-9.
1989: Wagner D K; Muelenaer P; Henderson F W; Snyder M H; Reimer C B; Walsh E E; Anderson L J; Nelson D L; Murphy B R
Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections.
Journal of clinical microbiology 1989;27(3):589-92.
1989: Clements M L; Sears S D; Christina K; Murphy B R; Snyder M H
Comparison of the virologic and immunologic responses of volunteers to live avian-human influenza A H3N2 reassortant virus vaccines derived from two different avian influenza virus donors.
Journal of clinical microbiology 1989;27(1):219-22.
1989: Olmsted R A; Murphy B R; Lawrence L A; Elango N; Moss B; Collins P L
Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus.
Journal of virology 1989;63(1):411-20.
1989: Murphy B R; Clements M L
The systemic and mucosal immune response of humans to influenza A virus.
Current topics in microbiology and immunology 1989;146():107-16.
1988: Sears S D; Clements M L; Betts R F; Maassab H F; Murphy B R; Snyder M H
Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults.
The Journal of infectious diseases 1988;158(6):1209-19.
1988: Olmsted R A; Buller R M; Collins P L; London W T; Beeler J A; Prince G A; Chanock R M; Murphy B R
Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus.
Vaccine 1988;6(6):519-24.
1988: Vasantha S; Coelingh K L; Murphy B R; Dourmashkin R R; Hammer C H; Frank M M; Fries L F
Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.
Virology 1988;167(2):433-41.
1988: Betts R F; Douglas R G; Maassab H F; DeBorde D C; Clements M L; Murphy B R
Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers.
Journal of medical virology 1988;26(2):175-83.
1988: Snyder M H; Banks S; Murphy B R
Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay.
Journal of clinical microbiology 1988;26(10):2034-40.
1988: Murphy B R; Olmsted R A; Collins P L; Chanock R M; Prince G A
Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
Journal of virology 1988;62(10):3907-10.
1988: Flexner C; Murphy B R; Rooney J F; Wohlenberg C; Yuferov V; Notkins A L; Moss B
Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen.
Nature 1988;335(6187):259-62.
1988: Murphy B R; Prince G A; Collins P L; Van Wyke Coelingh K; Olmsted R A; Spriggs M K; Parrott R H; Kim H W; Brandt C D; Chanock R M
Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
Virus research 1988;11(1):1-15.
1988: Murphy B R; Walsh E E
Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
Journal of clinical microbiology 1988;26(8):1595-7.
1988: Chanock R M; Murphy B R; Collins P L; Coelingh K V; Olmsted R A; Snyder M H; Spriggs M K; Prince G A; Moss B; Flores J
Live viral vaccines for respiratory and enteric tract diseases.
Vaccine 1988;6(2):129-33.
1988: Spriggs M K; Collins P L; Tierney E; London W T; Murphy B R
Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
Journal of virology 1988;62(4):1293-6.
1988: van Wyke Coelingh K L; Winter C C; Tierney E L; London W T; Murphy B R
Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.
The Journal of infectious diseases 1988;157(4):655-62.
1988: Snyder M H; Betts R F; DeBorde D; Tierney E L; Clements M L; Herrington D; Sears S D; Dolin R; Maassab H F; Murphy B R
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.
Journal of virology 1988;62(2):488-95.
1988: van Wyke Coelingh K L; Winter C C; Murphy B R
Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983.
Virology 1988;162(1):137-43.
1988: Murphy B R
Current approaches to the development of vaccines effective against parainfluenza viruses.
Bulletin of the World Health Organization 1988;66(3):391-7.
1987: Spriggs M K; Murphy B R; Prince G A; Olmsted R A; Collins P L
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
Journal of virology 1987;61(11):3416-23.
1987: Johnson P R; Olmsted R A; Prince G A; Murphy B R; Alling D W; Walsh E E; Collins P L
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.
Journal of virology 1987;61(10):3163-6.
1987: van Wyke Coelingh K L; Murphy B R; Collins P L; Lebacq-Verheyden A M; Battey J F
Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus.
Virology 1987;160(2):465-72.
1987: Snyder M H; Buckler-White A J; London W T; Tierney E L; Murphy B R
The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys.
Journal of virology 1987;61(9):2857-63.
1987: Paterson R G; Lamb R A; Moss B; Murphy B R
Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity.
Journal of virology 1987;61(6):1972-7.
1987: van Wyke Coelingh K L; Winter C C; Jorgensen E D; Murphy B R
Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities.
Journal of virology 1987;61(5):1473-7.
1987: Wagner D K; Nelson D L; Walsh E E; Reimer C B; Henderson F W; Murphy B R
Differential immunoglobulin G subclass antibody titers to respiratory syncytial virus F and G glycoproteins in adults.
Journal of clinical microbiology 1987;25(4):748-50.
1987: Wagner D K; Clements M L; Reimer C B; Snyder M; Nelson D L; Murphy B R
Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum.
Journal of clinical microbiology 1987;25(3):559-62.
1987: Brown T A; Clements M L; Murphy B R; Radl J; Haaijman J J; Mestecky J
Molecular form and subclass distribution of IgA antibodies after immunization with live and inactivated influenza A vaccines.
Advances in experimental medicine and biology 1987;216B():1691-700.
1986: Buckler-White A J; Murphy B R
Nucleotide sequence analysis of the nucleoprotein gene of an avian and a human influenza virus strain identifies two classes of nucleoproteins.
Virology 1986;155(2):345-55.
1986: Murphy B R; Alling D W; Snyder M H; Walsh E E; Prince G A; Chanock R M; Hemming V G; Rodriguez W J; Kim H W; Graham B S
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection.
Journal of clinical microbiology 1986;24(5):894-8.
1986: Snyder M H; Stephenson E H; Young H; York C G; Tierney E L; London W T; Chanock R M; Murphy B R
Infectivity and antigenicity of live avian-human influenza A reassortant virus: comparison of intranasal and aerosol routes in squirrel monkeys.
The Journal of infectious diseases 1986;154(4):709-11.
1986: Olmsted R A; Elango N; Prince G A; Murphy B R; Johnson P R; Moss B; Chanock R M; Collins P L
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(19):7462-6.
1986: Coelingh K J; Winter C C; Murphy B R; Rice J M; Kimball P C; Olmsted R A; Collins P L
Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies.
Journal of virology 1986;60(1):90-6.
1986: Snyder M H; Clements M L; Herrington D; London W T; Tierney E L; Murphy B R
Comparison by studies in squirrel monkeys, chimpanzees, and adult humans of avian-human influenza A virus reassortants derived from different avian influenza virus donors.
Journal of clinical microbiology 1986;24(3):467-9.
1986: Wagner D K; Graham B S; Wright P F; Walsh E E; Kim H W; Reimer C B; Nelson D L; Chanock R M; Murphy B R
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection.
Journal of clinical microbiology 1986;24(2):304-6.
1986: Murphy B R; Prince G A; Walsh E E; Kim H W; Parrott R H; Hemming V G; Rodriguez W J; Chanock R M
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
Journal of clinical microbiology 1986;24(2):197-202.
1986: Snyder M H; London W T; Tierney E L; Maassab H F; Murphy B R
Restricted replication of a cold-adapted reassortant influenza A virus in the lower respiratory tract of chimpanzees.
The Journal of infectious diseases 1986;154(2):370-1.
1986: Clements M L; Snyder M H; Buckler-White A J; Tierney E L; London W T; Murphy B R
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers.
Journal of clinical microbiology 1986;24(1):47-51.
1986: Clements M L; Betts R F; Tierney E L; Murphy B R
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus.
Journal of clinical microbiology 1986;24(1):157-60.
1986: Murphy B R; Graham B S; Prince G A; Walsh E E; Chanock R M; Karzon D T; Wright P F
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection.
Journal of clinical microbiology 1986;23(6):1009-14.
1986: Snyder M H; Clements M L; Betts R F; Dolin R; Buckler-White A J; Tierney E L; Murphy B R
Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
Journal of clinical microbiology 1986;23(5):852-7.
1986: Elango N; Prince G A; Murphy B R; Venkatesan S; Chanock R M; Moss B
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(6):1906-10.
1986: Prince G A; Jenson A B; Hemming V G; Murphy B R; Walsh E E; Horswood R L; Chanock R M
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.
Journal of virology 1986;57(3):721-8.
1986: Buckler-White A J; Naeve C W; Murphy B R
Characterization of a gene coding for M proteins which is involved in host range restriction of an avian influenza A virus in monkeys.
Journal of virology 1986;57(2):697-700.
1986: Tian S F; Buckler-White A J; London W T; Reck L J; Chanock R M; Murphy B R
[Nucleoprotein and membrane protein genes responsible for restriction of replication of influenza A/Mallard/NY/78 virus and its reassortants in the respiratory tract of squirrel monkeys]
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 1986;8(1):1-6.
1986: Clements M L; Betts R F; Tierney E L; Murphy B R
Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine.
Journal of clinical microbiology 1986;23(1):73-6.
1986: Clements M L; Murphy B R
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.
Journal of clinical microbiology 1986;23(1):66-72.
1985: Snyder M H; Clements M L; De Borde D; Maassab H F; Murphy B R
Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus.
Journal of clinical microbiology 1985;22(5):719-25.
1985: Hemming V G; Prince G A; Horswood R L; London W J; Murphy B R; Walsh E E; Fischer G W; Weisman L E; Baron P A; Chanock R M
Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model.
The Journal of infectious diseases 1985;152(5):1083-7.
1985: Brown T A; Murphy B R; Radl J; Haaijman J J; Mestecky J
Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans.
Journal of clinical microbiology 1985;22(2):259-64.
1985: Van Voris L P; Betts R F; Menegus M A; Murphy B R; Roth F K; Douglas R G
Serological diagnosis of influenza A/USSR/77 H1N1 infection: value of ELISA compared to other antibody techniques.
Journal of medical virology 1985;16(4):315-20.
1985: Murphy B R; Clements M L; Tierney E L; Black R E; Stienberg J; Chanock R M
Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers.
The Journal of infectious diseases 1985;152(1):225-9.
1985: Clements M L; Tierney E L; Murphy B R
Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine.
Journal of clinical microbiology 1985;21(6):997-9.
1985: van Wyke Coelingh K L; Winter C; Murphy B R
Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus.
Virology 1985;143(2):569-82.
1985: Burlington D B; Wright P F; van Wyke K L; Phelan M A; Mayner R E; Murphy B R
Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children.
Journal of clinical microbiology 1985;21(5):847-9.
1985: Betts R F; Douglas R G; Murphy B R
Resistance to challenge with influenza A/Hong Kong/123/77 (H1N1) wild-type virus induced by live attenuated A/Hong Kong/123/77 (H1N1) cold-adapted reassortant virus.
The Journal of infectious diseases 1985;151(4):744-5.
1985: Tian S F; Buckler-White A J; London W T; Reck L J; Chanock R M; Murphy B R
Nucleoprotein and membrane protein genes are associated with restriction of replication of influenza A/Mallard/NY/78 virus and its reassortants in squirrel monkey respiratory tract.
Journal of virology 1985;53(3):771-5.
1984: Murphy B R; Buckler-White A J; London W T; Harper J; Tierney E L; Miller N T; Reck L J; Chanock R M; Hinshaw V S
Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses.
The Journal of infectious diseases 1984;150(6):841-50.
1984: Tian S F; Zhang L X; Murphy B R
Characterization of the genotype and level of attenuation of an influenza A reassortant virus produced by mating the Xia-ts donor virus with A/Beijing/70 (H1N1) wild type virus.
Vaccine 1984;2(3):189-92.
1984: Murphy B R; Clements M L; Madore H P; Steinberg J; O'Donnell S; Betts R; Demico D; Reichman R C; Dolin R; Maassab H F
Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers.
The Journal of infectious diseases 1984;149(5):816.
1984: Clements M L; Betts R F; Maassab H F; Murphy B R
Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers.
The Journal of infectious diseases 1984;149(5):814-5.
1984: Clements M L; Betts R F; Murphy B R
Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection.
Lancet 1984;1(8379):705-8.
1984: van Wyke K L; Yewdell J W; Reck L J; Murphy B R
Antigenic characterization of influenza A virus matrix protein with monoclonal antibodies.
Journal of virology 1984;49(1):248-52.
1983: Smith G L; Murphy B R; Moss B
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.
Proceedings of the National Academy of Sciences of the United States of America 1983;80(23):7155-9.
1983: Murphy B R; Harper J; Sly D L; London W T; Miller N T; Webster R G
Evaluation of the A/Seal/Mass/1/80 virus in squirrel monkeys.
Infection and immunity 1983;42(1):424-6.
1983: Burlington D B; Clements M L; Meiklejohn G; Phelan M; Murphy B R
Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus.
Infection and immunity 1983;41(2):540-5.
1983: Hinshaw V S; Webster R G; Naeve C W; Murphy B R
Altered tissue tropism of human-avian reassortant influenza viruses.
Virology 1983;128(1):260-3.
1983: Wright P F; Murphy B R; Kervina M; Lawrence E M; Phelan M A; Karzon D T
Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory.
Infection and immunity 1983;40(3):1092-5.
1983: Clements M L; O'Donnell S; Levine M M; Chanock R M; Murphy B R
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus.
Infection and immunity 1983;40(3):1044-51.
1983: Shimizu K; Mullinix M G; Chanock R M; Murphy B R
Temperature-sensitive mutants of influenza A/Udorn/72 (H3N2) virus. III. Genetic analysis of temperature-dependent host range mutants.
Virology 1983;124(1):35-44.
1982: Murphy B R; Sly D L; Tierney E L; Hosier N T; Massicot J G; London W T; Chanock R M; Webster R G; Hinshaw V S
Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys.
Science (New York, N.Y.) 1982;218(4579):1330-2.
1982: Hobbins T E; Hughes T P; Rennels M B; Murphy B R; Levine M M
Bronchial reactivity in experimental infections with influenza virus.
The Journal of infectious diseases 1982;146(4):468-71.
1982: Murphy B R; Hinshaw V S; Sly D L; London W T; Hosier N T; Wood F T; Webster R G; Chanock R M
Virulence of avian influenza A viruses for squirrel monkeys.
Infection and immunity 1982;37(3):1119-26.
1982: Murphy B R; Markoff L J; Hosier N T; Massicot J G; Chanock R M
Production and level of genetic stability of an influenza A virus temperature-sensitive mutant containing two genes with ts mutations.
Infection and immunity 1982;37(1):235-42.
1982: Murphy B R; Nelson D L; Wright P F; Tierney E L; Phelan M A; Chanock R M
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.
Infection and immunity 1982;36(3):1102-8.
1982: Brundage-Anguish L J; Holmes D F; Hosier N T; Murphy B R; Massicott J G; Appleyard G; Coggins L
Live temperature-sensitive equine influenza virus vaccine: generation of the virus and efficacy in hamsters.
American journal of veterinary research 1982;43(5):869-74.
1982: Tolpin M D; Clements M L; Levine M M; Black R E; Saah A J; Anthony W C; Cisneros L; Chanock R M; Murphy B R
Evaluation of a phenotypic revertant of the A/Alaska/77-ts-1A2 reassortant virus in hamsters and in seronegative adult volunteers: further evidence that the temperature-sensitive phenotype is responsible for attenuation of ts-1A2 reassortant viruses.
Infection and immunity 1982;36(2):645-50.
1982: Massicot J G; Van Wyke K; Chanock R M; Murphy B R
Evidence for intrasegmental complementation between two influenza A viruses having ts mutations on their P1 genes.
Virology 1982;117(2):496-500.
1982: Shimizu K; Mullinix M G; Chanock R M; Murphy B R
Temperature-sensitive mutants of influenza A/Udorn/72 (H3N2) virus. II. Genetic analysis and demonstration of intrasegmental complementation.
Virology 1982;117(1):45-61.
1982: Shimizu K; Mullinix M G; Chanock R M; Murphy B R
Temperature-sensitive mutants of influenza A/Udorn/72 (H3N2) virus. I. Isolation of temperature-sensitive mutants some of which exhibit host-dependent temperature sensitivity.
Virology 1982;117(1):38-44.
1981: Yarchoan R; Murphy B R; Strober W; Schneider H S; Nelson D L
Specific anti-influenza virus antibody production in vitro by human peripheral blood mononuclear cells.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(6):2588-94.
1981: Yarchoan R; Murphy B R; Strober W; Clements M L; Nelson D L
In vitro production of anti-influenza virus antibody after intranasal inoculation with cold-adapted influenza virus.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(5):1958-63.
1981: Tolpin M D; Massicot J G; Mullinix M G; Kim H W; Parrott R H; Chanock R M; Murphy B R
Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo.
Virology 1981;112(2):505-17.
1981: Murphy B R; Maassab H F; Wood F T; Chanock R M
Characterization of the temperature sensitive phenotype of the A/Ann Arbor/6/60 cold-adapted virus and its recombinants.
Infection and immunity 1981;32(2):960-3.
1981: Murphy B R; Chanock R M; Clements M L; Anthony W C; Sear A J; Cisneros L A; Rennels M B; Miller E H; Black R E; Levine M M; Betts R F; Douglas R G; Maassab H F; Cox N J; Kendal A P
Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteers.
Infection and immunity 1981;32(2):693-7.
1981: Murphy B R; Phelan M A; Nelson D L; Yarchoan R; Tierney E L; Alling D W; Chanock R M
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses.
Journal of clinical microbiology 1981;13(3):554-60.
1980: Massicot J G; Murphy B R; van Wyke K; Huang K Y; Chanock R M
ts P1 and P3 genes are responsible for satisfactory level of attenuation of ts-1A2 recombinants bearing H1N1 or H3N2 surface antigens of influenza A virus.
Virology 1980;106(1):187-90.
1980: Yolken R H; Torsch V M; Berg R; Murphy B R; Lee Y C
Fluorometric assay for measurement of viral neuraminidase--application to the rapid detection of influenza virus in nasal wash specimens.
The Journal of infectious diseases 1980;142(4):516-23.
1980: Murphy B R; Rennels M B; Douglas R G; Betts R F; Couch R B; Cate T R; Chanock R M; Kendal A P; Maassab H F; Suwanagool S; Sotman S B; Cisneros L A; Anthony W C; Nalin D R; Levine M M
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers.
Infection and immunity 1980;29(2):348-55.
1980: Murphy B R; Tierney E L; Barbour B A; Yolken R H; Alling D W; Holley H P; Mayner R E; Chanock R M
Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines.
Infection and immunity 1980;29(2):342-7.
1980: Murphy B R; Hosier N T; Chanock R M
Temperature-sensitive mutants of influenza A virus: transfer of the two temperature-sensitive lesions in the Udorn/72-ts-1A2 virus to the A2Hong Kong/123/77 (H1N1) wild-type virus.
Infection and immunity 1980;28(3):792-8.
1980: Murphy B R; Sly D L; Hosier N T; London W T; Chanock R M
Evaluation of three strains of influenza A virus in humans and in owl, cebus, and squirrel monkeys.
Infection and immunity 1980;28(3):688-91.
1980: Chanock R M; Murphy B R
Use of temperature-sensitive and cold-adapted mutant viruses in immunoprophylaxis of acute respiratory tract disease.
Reviews of infectious diseases 1980;2(3):421-32.
1980: Berg R A; Yolken R H; Rennard S I; Dolin R; Murphy B R; Straus S E
New enzyme immunoassays for measurement of influenza A/Victoria/3/75 virus in nasal washes.
Lancet 1980;1(8173):851-3.
1980: Massicot J G; Murphy B R; Thierry F; Markoff L; Huang K Y; Chanock R M
Temperature-sensitive mutants of influenza virus. Identification of the loci of the two ts lesions in the Udorn-ts-1A2 donor virus and the correlation of the presence of these two ts lesions with a predictable level of attenuation.
Virology 1980;101(1):242-9.
1980: Murphy B R; Markoff L J; Chanock R M; Spring S B; Maassab H F; Kendal A P; Cox N J; Levine M M; Douglas R G; Betts R F; Couch R B; Cate T R
Genetic approaches to attenuation of influenza A viruses for man.
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 1980;288(1029):401-15.
1980: Murphy B R; Wood F T; Massicot J G; Chanock R M
Temperature-sensitive mutants of influenza A virus. Transfer of the two ts-1A2 ts lesions present in the Udorn/72-ts-1A2 donor virus to the influenza A/Alaska/6/77 (H3N2) wild type virus.
Archives of virology 1980;65(2):175-86.
1980: Murphy B R; Chanock R M; Douglas R G; Betts R F; Waterman D H; Holley H P; Hoover D L; Suwanagool S; Nalin D R; Levine M M
Temperature-sensitive mutants of influenza A virus: evaluation of the Alaska/77-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers.
Archives of virology 1980;65(2):169-73.
1980: Murphy B R; Tolpin M D; Massicot J G; Kim H Y; Parrott R H; Chanock R M
Escape of a highly defective influenza A virus mutant from its temperature sensitive phenotype by extragenic suppression and other types of mutation.
Annals of the New York Academy of Sciences 1980;354():172-82.
1979: Markoff L J; Thierry F; Murphy B R; Chanock R M
Relationship of genotype of recombinants of influenza A/Hong Kong/68-ts-1[E]virus used as live virus vaccines to virulence in humans.
Infection and immunity 1979;26(1):280-6.
1979: Douglas R G; Markoff L J; Murphy B R; Chanock R M; Betts R F; Hayden F G; Levine M M; Van Blerk G A; Sotman S B; Nalin D R
Live Victoria/75-ts-1[E] influenza A virus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus.
Infection and immunity 1979;26(1):274-9.
1979: Richman D D; Murphy B R
The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines.
Reviews of infectious diseases 1979;1(3):413-33.
1979: Murphy B R; Holley H P; Berquist E J; Levine M M; Spring S B; Maassab H F; Kendal A P; Chanock R M
Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain.
Infection and immunity 1979;23(2):253-9.
1979: Murphy B R; Chanock R M; Levine M M; van Blerk G A; Berquist E J; Douglas R G; Betts R F; Couch R B; Cate T R
Temperature-sensitive mutants of influenza A virus: evaluation of the A/Victoria/75-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers.
Infection and immunity 1979;23(2):249-52.
1979: Markoff L J; Murphy B R; Kendal A J; Chanock R M
Probable association of plaque size with neuraminidase subtype among H3N2 influenza A viruses. Brief report.
Archives of virology 1979;62(3):277-80.
1979: Chanock R M; Murphy B R
Genetic approaches to control of influenza.
Perspectives in biology and medicine 1979;22(2 Pt 2):S37-S48.
1979: Murphy B R; Chanock R M
Present status of live influenza A virus vaccine.
Monographs in paediatrics 1979;11():1-20.
1979: Reichman R C; Pons V G; Murphy B R; Caplan E A; Dolin R
Cell-mediated cytotoxicity following influenza infection and vaccination in humans.
Journal of medical virology 1979;4(1):1-14.
1978: Murphy B R; Wood F T; Massicot J G; Chanock R M
Temperature-sensitive mutants of influenza virus. XVI. Transfer of the two ts lesions present in the Udorn/72-ts-1A2 donor virus to the Victoria/3/75 wild-type virus.
Virology 1978;88(2):244-51.
1978: Murphy B R; Wood F T; Massicot J G; Spring S B; Chanock R M
Temperature-sensitive mutants of influenza virus. XV. The genetic and biological characterization of a recombinant influenza virus containing two ts lesions produced by mating two complementing, single lesion ts mutants.
Virology 1978;88(2):231-43.
1978: Grizzard M B; London W T; Sly D L; Murphy B R; James W D; Parnell W P; Chanock R M
Experimental production of respiratory tract disease in cebus monkeys after intratracheal or intranasal infection with influenza A/Victoria/3/75 or influenza A/New Jersey/76 virus.
Infection and immunity 1978;21(1):201-5.
1978: Murphy B R; Markoff L J; Hosier N T; Rusten H M; Chanock R M; Kendal A P; Douglas R G; Betts R F; Cate T R; Couch R B; Levine M M; Waterman D H; Holley H P
Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-1[E] recombinant viruses in volunteers.
Infection and immunity 1978;20(3):671-7.
1978: Murphy B R; Hosier N T; Spring S B; Mostow S R; Chanock R M
Temperature-sensitive mutants of influenza A virus: production and characterization of A/Victoria/3/75-ts-1[E] recombinants.
Infection and immunity 1978;20(3):665-70.
1978: Dolin R; Murphy B R; Caplan E A
Lymphocyte blastogenic responses to influenza virus antigens after influenza infection and vaccination in humans.
Infection and immunity 1978;19(3):867-74.
1978: Scholtissek C; Murphy B R
Host range mutants of an influenza A virus.
Archives of virology 1978;58(4):323-33.
1977: Richman D D; Murphy B R; Chanock R M
Demonstration of a non-temperature-sensitive growth-restricting mutation in a ts mutant of influenza A virus: implications for live virus vaccine development.
Virology 1977;83(2):356-64.
1977: Easterday B C; Murphy B R; McGregor S
Infection and vaccination of pigs with influenza A/New Jersey/8/76 (Hsw1N1) virus.
The Journal of infectious diseases 1977;136 Suppl():S699-702.
1977: Massicot J; Murphy B R
Comparison of the hemagglutination-inhibiting and neutralizing antibody responses of volunteers given 400 chick cell-agglutinating units of influenza A/New Jersey/76 split-virus vaccine.
The Journal of infectious diseases 1977;136 Suppl():S472-4.
1977: Kendal A P; Cox N J; Murphy B R; Spring S B; Maassab H F
Comparative studies of wild-type and 'cold-mutant' (temperature sensitive) influenza viruses: geneology of the matrix (M) and non-structural (NS) proteins in recombinant cold-adapted H3N2 viruses.
The Journal of general virology 1977;37(1):145-59.
1977: Richman D D; Murphy B R; Belshe R B; Rusten H M; Chanock R M; Blacklow N R; Parrino T A; Rose F B; Levine M M; Caplan E
Temperature-sensitive mutants of influenza A virus. XIV. Production and evaluation of influenza A/Georgia/74-ts-1[E] recombinant viruses in human adults.
The Journal of infectious diseases 1977;136(2):256-62.
1977: Mostow S R; Flatauer S; Paler M; Murphy B R
Temperature-sensitive mutants of influenza virus. XIII. Evaluation of influenza A/Hong Kong/68 and A/Udorn/72 ts and wild-type viruses in tracheal organ culture at permissive and restrictive temperatures.
The Journal of infectious diseases 1977;136(1):1-6.
1977: Murphy B R; Markoff L J; Chanock R M; Douglas R G; Betts R F; Cate T R; Couch R B
An evaluation of influenza A/Victoria/3/75-ts-1 [E] recombinant viruses for attenuation and immunogenicity in adult seronegative volunteers.
Developments in biological standardization 1977;39():47-52.
1977: Maassab H F; Cox N J; Murphy B R; Kendal A P
Biological, genetic and biochemical characterization of a cold-adapted recombinant A/Victoria/3/75 virus and its evaluation in volunteers.
Developments in biological standardization 1977;39():25-31.
1977: Dolin R; Richman D D; Murphy B R; Fauci A S
Cell-mediated immune responses in humans after induced infection with influenza A virus.
The Journal of infectious diseases 1977;135(5):714-9.
1977: Spring S B; Maassab H F; Kendal A P; Murphy B R; Chanock R M
Cold-adapted variants of influenza virus A. I. Comparison of the genetic properties of ts mutants and five cold-adapted variants of influenza virus A.
Virology 1977;77(1):337-43.
1977: Spring S B; Maassab H F; Kendal A P; Murphy B R; Chanock R M
Cold adapted variants of influenza A. II. Comparison of the genetic and biological properties of ts mutants and recombinants of the cold adapted A/AA/6/60 strain.
Archives of virology 1977;55(3):233-46.
1976: Richman D D; Murphy B R; Chanock R M; Gwaltney J M; Douglas R G; Betts R F; Blacklow N R; Rose F B; Parrino T A; Levine M M; Caplan E S
Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults.
The Journal of infectious diseases 1976;134(6):585-94.
1976: Murphy B R; Tierney E L; Spring S B; Chanock R M
Temperature-sensitive mutants of influenza A virus. XI. Transfer of ts lesions in the Hong Kong/68-ts-1 [a] virus to the influenza A/Udorn/72 wild type.
The Journal of infectious diseases 1976;134(6):577-84.
1976: Murphy B R; Richman D D; Spring S B; Chanock R M
Use of temperature-sensitive mutants of influenza A virus as live virus vaccine strains. Evaluation in laboratory animals, adults and children.
Postgraduate medical journal 1976;52(608):381-8.
1976: Kim H W; Arrobio J O; Brandt C D; Parrott R H; Murphy B R; Richman D D; Chanock R M
Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen.
Pediatric research 1976;10(4):238-42.
1976: Richman D D; Murphy B R; Baron S; Uhlendorf C
Three strains of influenza A virus (H3N2): interferon sensitivity in vitro and interferon production in volunteers.
Journal of clinical microbiology 1976;3(3):223-6.
1976: Douglas R G; Bentley D W; Betts R F; Zaky D A; Roth F K; Murphy B R
Evaluation of a temperature-sensitive influenza virus in elderly and chronically ill subjects.
The American review of respiratory disease 1976;113(3):293-300.
1976: Hall W H; Douglas R G; Zaky D A; Hyde R W; Richman D; Murphy B R
Attenuated influenza virus in normal adults: role of pulmonary function studies in vaccine trials.
The Journal of infectious diseases 1976;133(2):145-52.
1975: Murphy B R; Spring S B; Richman D D; Tierney E L; Kasel J; Chanock R M
Temperature-Sensitive mutants of influenza virus. VII. Transfer of the TS-1[E] lesions to a wild-type influenza A virus with the HON1 surface antigens.
Virology 1975;66(2):533-41.
1975: Spring S B; Nusinoff S R; Mills J; Richman D D; Tierney E L; Murphy B R; Chanock R M
Temperature-sensitive mutants of influenza virus. VI. Transfer of TS lesions from the Asian subtype of influenza A virus (H2N2) to the Hong Kong subtype (H3N2).
Virology 1975;66(2):522-32.
1975: Richman D D; Murphy B R; Spring S B; Coleman M T; Chanock R M
Temperature sensitive mutants of influenza virus. IX. Genetic and biological characterization of TS-1[E] lesions when transferred to a 1972 (H3N2) influenza A virus.
Virology 1975;66(2):551-62.
1975: Spring S B; Nusinoff S R; Tierney E L; Richman D D; Murphy B R; Chanock R M
Temperature-sensitive mutants of influenza. VIII. Genetic and biological characterization of TS mutants of influenza virus A (H3N2) and their assignment to complementation groups.
Virology 1975;66(2):542-50.
1975: Murphy B R; Richman D D; Chalhub E G; Uhlendorf C P; Baron S; Chanock R M
Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus.
Infection and immunity 1975;12(1):62-8.
1975: Richman D D; Murphy B R; Cline W L; Alling D W
Determination of influenzavirus neuraminidase inhibition titres.
Bulletin of the World Health Organization 1975;52(2):233-4.
1974: Richman D D; Murphy B R; Tierney E L; Chanock R M
Specificity of the local secretory antibody to influenza A virus infection.
Journal of immunology (Baltimore, Md. : 1950) 1974;113(5):1654-6.
1974: Murphy B R; Hodes D S; Nusinoff S R; Spring-Stewart S; Tierney E L; Chanock R M
Temperature-sensitive mutants of influenza virus. V. Evaluation in man of an additional ts recombinant virus with a 39 C shutoff temperature.
The Journal of infectious diseases 1974;130(2):144-9.
1973: Murphy B R; Baron S; Chalhub E G; Uhlendorf C P; Chanock R M
Temperature-sensitive mutants of influenza virus. IV. Induction of interferon in the nasopharynx by wild-type and a temperature-sensitive recombinant virus.
The Journal of infectious diseases 1973;128(4):488-93.
1973: Murphy B R; Chalhub E G; Nusinoff S R; Kasel J; Chanock R M
Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man.
The Journal of infectious diseases 1973;128(4):479-87.
1973: Parrott R H; Kim H W; Arrobio J O; Hodes D S; Murphy B R; Brandt C D; Camargo E; Chanock R M
Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.
American journal of epidemiology 1973;98(4):289-300.
1972: Murphy B R; Chalhub E G; Nusinoff S R; Chanock R M
Temperature-sensitive mutants of influenza virus. II. Attenuation of ts recombinants for man.
The Journal of infectious diseases 1972;126(2):170-8.
1972: Murphy B R; Kasel J A; Chanock R M
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
The New England journal of medicine 1972;286(25):1329-32.
1968: Murphy B R; Glasgow L A
Factors modifying host resistance to viral infection. 3. Effect of whole body x-irradiation on experimental encephalomyocarditis virus infection in mice.
The Journal of experimental medicine 1968;127(5):1035-52.
1967: Murphy B R; Glasgow L A
Factors modifying host resistance to viral infection. I. Effect of immunosuppressive drugs on experimental infection of mice with encephalomyocarditis virus.
Antimicrobial agents and chemotherapy 1967;7():661-7.

Sign-in to see more